1 minute read
Mar. 13, 2023

MRTX1133: 2022 MOTY Nominee

Mirati/Array/Pfizer KRAS(G12D) inhibitor

oral, BID, reversible KRAS(G12D) inhibitor entering Ph. I/II for KRAS(G12D)-mutated tumors from SBDD of KRASG12C inhibitor MRTX1133 Mirati Therapeutics, San Diego, CA; Pfizer, Boulder, CO (formerly Array)


Molecules of the Month

MOTY Nominees

Molecule of the Year